The Evaluation of Safety and Efficacy of Epirubicin Combined with Oxaliplatin and 5-Fluorouracil for Patients with Advanced/metastatic Gastric Cancer
ZHU Xiao-dong,WANG Bi-yun,CAO Jun-ning,CAO Dong,HONG Xiao-nan,YIN Ji-liang
DOI: https://doi.org/10.3969/j.issn.1007-3639.2006.05.011
2006-01-01
Abstract:Background and purpose:There is still no standard chemotherapy regimen for advanced or metastatic gastric cancer,and there are only a few regimens such as ECF regimen(epirubicin,cisplatin and 5-fluorouracil) to be evaluated,the efficacy of ECF has been confirmed by phase Ⅲ clinical trails,but it is very inconvenient for patients to complete continuous injection of 5-FU for 21days and the side effects are serious.Nowadays,some studies have proved that oxaliplatin was better than cisplatin in the treatment of gastric cancer,and also the adverse effect was much milder.In order to improve the efficacy and safety,we modified the ECF regimen into the EOF_5 regimen in which we substitute oxaliplatin for cisplatin and change the way of delivery of 5Fu from continuous injection of 5-FU for 21days to 5 days.Our purpose is to evaluate the efficacy and safety of EOF regimen for patients with advanced/metastatic gastric cancer.Methods:Patients who entered into this study received the treatment of epirubicin 50mg/m~(2) iv at day1,oxaliplatin 130mg/m~(2) iv gtt at day1 and 5-fluorouracil 375-425mg/m~(2).day 1~day 5(for 120hr),and repeated every 3 weeks.Efficacy was analyzed every 2 cycles along with the safety and quality of life(QOL).Results:Seventeen patients(6 patients with primary lesions unresectable,11 with metastases after primary tumor resection) were included into this study.Sixteen patients were suitable for the analysis.2 patients achieved CR(12.5%),5 PR(31.3%),8 SD(50%),1 PD(6.3%).In 14 patients who received ECF as the first line treatment,the ORR is 50%,total of 64 cycles of treatment were conducted in 17 patients,with Grade 3,4 WHO toxicity of neutropenia in 4 cycles(6.3%),anemia in 1 cycle(1.6%),thrombocytopenia in 1 cycle(1.6%),nausea/vomiting 2 cycle(3.2%),mucositis 1 cycle(1.6%),peripheral nuropathy toxicity in 1 cycle(1.6%) and phlebitis in 1 cycle(1.6%).There was no Grade 4 WHO toxicity except thrombocytopenia.There were no drug related heart dysfunction,arrhythmia,abnormality of alanine aminotransferase or creatinine.No treatment related death occurred in this trail.Conclusions:EOF_(5) regimen was well tolerated and very effective for the treatment of patients with advanced gastric cancer.It could be used as the first line of treatment,but its efficacy,TTP,and overall survival still need to be further investigated.